Screening MRI for brain disease in advanced lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the value of conducting MRI scans of the brain in patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) who are asymptomatic and fit for systemic treatment. The aim is to identify any undetected brain metastases that may influence treatment decisions. Participants will undergo an MRI to screen for brain disease, which is crucial for managing their overall treatment plan. The study focuses on patients who do not have any symptoms of brain involvement and are not candidates for curative treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.
* Fit for systemic treatment (PS 0-2) according to standard of care.
* No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.

Exclusion Criteria:

* Prior/concomitant therapy for stage IV disease.
* Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.
* Contraindications for MRI scan with contrast as per standard of care protocol of the institution.

Where it's running

• University Medical Center Groningen
  Groningen, Provincie Groningen, Netherlands Recruiting
• Maastricht UMC+
  Maastricht, Netherlands Recruiting
• Ommelander Ziekenhuisgroep
  Scheemda, Netherlands Recruiting

Study contacts

• Study coordinator: F. Bensch, MD, PhD
• Email: f.bensch@umcg.nl
• Phone: 0031503616161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• Proteomic-guided, risk-adapted therapy for advanced non-small cell lung cancer

  This trial tests whether using a proteomic test plus a toxicity risk tool to pick immune checkpoint inhibitor–based treatment can improve 12-month progression-free survival for people with previously untreated advanced non-small cell lung cancer.

  Recruiting at 4 sites Phase 2 University of California, Davis · Chico, California and 3 other locations · NCT07250477

• First-line nivolumab plus ipilimumab with short-course chemotherapy for metastatic non-small cell lung cancer

  This project will collect real-world data to see if nivolumab plus ipilimumab combined with a short course of platinum chemotherapy works well as first-line treatment for adults with metastatic non-small cell lung cancer who do not have EGFR or ALK alterations.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07190677

• PF-08046054 (SGN-PDL1V) versus docetaxel for PD-L1–positive advanced non-small cell lung cancer

  This test compares PF-08046054 (SGN-PDL1V) with docetaxel for adults whose PD-L1–positive advanced NSCLC progressed after PD-1/PD-L1 inhibitors, platinum chemotherapy, and targeted treatments when appropriate.

  Recruiting at 454 sites Phase 3 Pfizer · Alabaster, Alabama and 468 other locations · NCT07144280

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.